|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:alternativeName
|
gliptins
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
gptkb:sitagliptin
|
|
gptkbp:ATCCode
|
A10BH
|
|
gptkbp:combines
|
gptkb:metformin
gptkb:thiazolidinediones
gptkb:insulin
sulfonylureas
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:decrease
|
glucagon secretion
|
|
gptkbp:discoveredIn
|
2000s
|
|
gptkbp:drugInteraction
|
gptkb:rifampin
gptkb:digoxin
|
|
gptkbp:effectOnHbA1c
|
modest reduction
|
|
gptkbp:example
|
gptkb:alogliptin
gptkb:sitagliptin
gptkb:saxagliptin
linagliptin
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DPP-4 inhibitors
|
|
gptkbp:improves
|
insulin secretion
incretin levels
|
|
gptkbp:legalStatus
|
varies by agent
|
|
gptkbp:marketedAs
|
gptkb:Boehringer_Ingelheim
gptkb:Takeda
gptkb:AstraZeneca
gptkb:Merck_&_Co.
|
|
gptkbp:mechanismOfAction
|
inhibit dipeptidyl peptidase-4 enzyme
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
liver function
renal function
|
|
gptkbp:notableFor
|
low risk of hypoglycemia
weight neutrality
|
|
gptkbp:pregnancyCategory
|
C (varies by agent)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:rareAdverseEffect
|
gptkb:bullous_pemphigoid
joint pain
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
pancreatitis
upper respiratory tract infection
nasopharyngitis
|
|
gptkbp:target
|
gptkb:DPP-4_enzyme
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Glucophage
gptkb:DB00162
|
|
gptkbp:bfsLayer
|
6
|